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Higher maternal leptin levels at second
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greater gestational weight gain in late
pregnancy
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Abstract
Background: Excessive gestational weight gain (GWG) is associated with adverse pregnancy outcomes. In
non-pregnant populations, low leptin levels stimulate positive energy balance. In pregnancy, both the placenta
and adipose tissue contribute to circulating leptin levels. We tested whether maternal leptin levels are associated with
subsequent GWG and whether this association varies depending on stage of pregnancy and on maternal body mass
index (BMI).
Methods: This prospective cohort study included 675 pregnant women followed from 1st trimester until delivery. We
collected anthropometric measurements, blood samples at 1st and 2nd trimester, and clinical data until delivery.
Maternal leptin was measured by ELISA (Luminex technology). We classified women by BMI measured at 1st
trimester: BMI < 25 kg/m2 = normal weight; 25 ≤ BMI < 30 kg/m2 = overweight; and BMI ≥ 30 kg/m2 = obese.
Results: Women gained a mean of 6.7 ± 3.0 kg between 1st and 2nd trimester (mid pregnancy GWG) and 5.6 ± 2.5 kg
between 2nd and the end of 3rd trimester (late pregnancy GWG). Higher 1st trimester leptin levels were associated
with lower mid pregnancy GWG, but the association was no longer significant after adjusting for % body fat
(%BF; β = 0.38 kg per log-leptin; SE = 0.52; P = 0.46). Higher 2nd trimester leptin levels were associated with greater
late pregnancy GWG and this association remained significant after adjustment for BMI (β = 2.35; SE = 0.41; P < 0.0001)
or %BF (β = 2.01; SE = 0.42; P < 0.0001). In BMI stratified analyses, higher 2nd trimester leptin levels were associated with
greater late pregnancy GWG in normal weight women (β = 1.33; SE = 0.42; P = 0.002), and this association was stronger
in overweight women (β = 2.85; SE = 0.94; P = 0.003 – P for interaction = 0.05).
Conclusions: Our results suggest that leptin may regulate weight gain differentially at 1st versus 2nd trimester of
pregnancy: at 2nd trimester, higher leptin levels were associated with greater subsequent weight gain – the opposite of
its physiologic regulation in non-pregnancy – and this association was stronger in overweight women. We suspect the
existence of a feed-forward signal from leptin in second half of pregnancy, stimulating a positive energy balance and
leading to greater weight gain.
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Background
Excessive gestational weight gain (GWG) and pre-
pregnancy obesity are associated with higher risk of
adverse pregnancy outcomes, such as macrosomia,
gestational diabetes mellitus (GDM), preeclampsia,
and caesarean delivery [1]. Several factors influence GWG,
including quality of diet, physical activity levels, pre-
pregnancy body mass index (BMI), maternal age and
parity [2, 3]. The physiologic regulation of GWG is
highly variable from one woman to another [4]; a few
pregnancy-related hormones such as progesterone have
been suggested to participate in GWG regulation [5]
but most endogenous regulators are still unknown.
Leptin is an adipokine secreted mainly from adipocytes
that circulates in proportion to white adipose tissue
mass in non-pregnant individuals [6], reflecting energy
stores in adipose tissue. Leptin is known for its role in
energy homeostasis: monogenic leptin deficiency is as-
sociated with hyperphagia and morbid obesity in both
animals and humans [7–9]. However, leptin resistance
also appears to exist in obese individuals since higher
endogenic leptin levels or exogenic leptin administration
does not reduce weight in humans [10, 11]. In a physio-
logic framework, lower leptin levels are associated with in-
creased weight gain in normal-weight young adults [12]
and with greater weight regain after weight loss in obese
individuals [13].
In pregnancy, the placenta is a substantial source of
circulating leptin and levels increase throughout pregnancy
[14, 15]. This seems counter-intuitive to leptin’s classic
physiological role, as pregnancy should be a state where the
energy signalling pathways favour a positive balance by in-
creasing food intake. While we know that adiposity accu-
mulation leads to higher leptin levels [15–19], how leptin
may conversely act as regulator of subsequent weight gain
in pregnancy is less understood. Current literature on this
topic is sparse and inconclusive because of inconsistencies
in study design – leptin levels measured before, during or
after weight gain assessment – and incomplete adjustment
for potential confounders [19–21]. Thus, we present here
our prospective study designed to assess the associations
between baseline leptin levels and subsequent GWG in a
large population-based cohort of pregnant women, taking
into account maternal adiposity status and period of the
pregnancy.
Methods
We recruited pregnant women at 1st trimester (5–16
weeks) of pregnancy and followed them until delivery in
the prospective cohort study Glycemic regulation in
Gestation and Growth (Gen3G). Pregnant women arriv-
ing for their 1st trimester blood sample visit between
January 2010 and July 2013 were invited to participate
in our study if they expected to deliver at the Centre
Hospitalier Universitaire de Sherbrooke (CHUS). We
excluded women who had any of the following criteria:
age <18 years old, multiple pregnancy, pregestational
diabetes (type 1 or 2) or diabetes discovered at 1st trimes-
ter (criteria based on 2008 Canadian Diabetes Association
guidelines [22]), drugs and/or alcohol abuse, uncontrolled
endocrine disease, or other major medical conditions (for
attrition and further details, see [23]). The CHUS human-
research ethics committee approved the project and all
women gave written informed consent before they were
included in the study, in accordance with the Declaration
of Helsinki.
During their 1st visit, we collected demographics and
baseline characteristics of participants, including mater-
nal age, ethnic background, gestational age (confirmed
by echography), parity, and personal and familial medical
history. In order to collect data on lifestyle, we used vali-
dated questionnaires concerning nutrition and physical
activity adapted from the Canadian Community Health
Survey [24]. Anthropometric measurements including
weight (kg; by a calibrated electronic scale, bare feet, in
light clothing), height (m), BMI (kg/m2), % body fat
(%BF; estimated by electrical bioimpedance using a stand-
ing foot-to-foot scale) and systolic and diastolic blood
pressures were performed according to standardized
procedures as described previously [25]. The majority
of women (97%) also performed a 50g glucose challenge
test with glucose levels measured 1-h after glucose inges-
tion, for early screening of GDM. We collected random
non-fasting blood samples in the remaining participants.
At 2nd trimester (23–30 weeks), all women performed
a 75g oral glucose tolerance test (OGTT) under fasting
state for routine GDM diagnosis based on International
Association of Diabetes and Pregnancy Study Groups
criteria [26]. We collected extra fasting blood samples
and at 1-h and 2-h during the OGTT for further ana-
lyses. Measures of glucose and insulin over the course
of the OGTT allowed determination of dynamic indi-
ces of insulin sensitivity and secretion, respectively;
Matsuda index (validated in pregnancy [27]), 10,000/
[square root (fasting glucose × fasting insulin) × (mean
glucose × mean insulin)] [28]; and total area under the
curve (AUC)insulin/glucose was calculated using the trap-
ezoidal rule applied to the insulin and glucose curves
during the OGTT. We collected data concerning any
medical updates since the last visit and repeated the
nutrition and physical activity questionnaires. Once
again, we measured anthropometry, according to the
same standardized procedures. We calculated maternal
GWG (kg) between 1st and 2nd trimester (mid pregnancy
GWG) by subtracting 1st trimester from 2nd trimester
maternal measured weights.
At the end of the 3rd trimester, we collected maternal
weight (kg) based on the last prenatal visit (34–42 weeks
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of gestation) available in our electronic medical records
(EMR). From the EMR, we additionally collected medical
events from 2nd trimester to delivery for any additional
major complications (premature deliveries, GDM, and
pre-eclampsia) and placental and birth weights recorded
by clinical staff at delivery. Women lost to follow-up did
not differ from the ones followed until delivery [23]. We
calculated maternal weight gain between 2nd and 3rd tri-
mester (late pregnancy GWG) by subtracting 2nd trimester
from 3rd trimester maternal weights.
Laboratory measurements
All blood samples collected at 1st and 2nd trimester were
maintained at 4°C and centrifuged. Plasma was distributed
in aliquots and stored at −80°C until measurements.
Plasma leptin and insulin levels were measured by
enzyme-linked immunosorbent assay (ELISA Luminex
technology; Millipore Corp, Billerica, MA, USA). Plasma
glucose levels were measured by glucose hexokinase
(Roche Diagnostics, Indianapolis, IN, USA). Intra- and
inter-assays coefficients of variation for leptin levels were
respectively of 3 and 4%.
Statistical analyses
From all women followed until delivery, we excluded
pregnancies with major complications (prematurity <37
weeks, pre-eclampsia) and missing data for weight or
leptin levels at any of the time points. Participants ex-
cluded for complications, missing data or lost to follow-up
(n = 288) were similar to women remaining in our dataset
(n = 736) in terms of maternal age, ethnicity and pre-
pregnancy BMI (all P > 0.05). We further excluded women
diagnosed with GDM (n = 61) for this analysis because
diagnosis and treatment of GDM greatly influence GWG.
This report included 675 normoglycemic pregnant women
who had a complete dataset from 1st trimester to delivery,
including all necessary maternal weight and leptin levels.
Characteristics of participants are presented as means ±
standard deviations if normally distributed or as median
and interquartile ranges otherwise; categorical variables
are presented as percentage. Continuous variables not
normally distributed were log-transformed and we used
log-transformed variables for correlations and linear
regression models when appropriate; leptin levels were
normally distributed after log-transformation. We per-
formed correlation analyses (Pearson and Spearman as
appropriate) to assess variables associated cross-sectionally
with leptin levels and to evaluate potential confounders.
We conducted linear regression analyses to assess associa-
tions between leptin levels (per one log increase) and subse-
quent GWG (using kg/week to standardize for different
follow-up time), taking into account potential confounding
factors. We first adjusted for gestational weeks and BMI
(model 2a) measured cross-sectionally with leptin levels of
interest at each time period assessed: for example the
model testing the association between leptin at 1st trimester
and subsequent GWG was adjusted for gestational age and
BMI measured at 1st trimester. We then adjusted for %BF
instead of BMI to account for adiposity per se (model 3a).
We additionally adjusted for systolic and diastolic blood
pressures, physical activity, quantity of fruits and vegetables
consumed per day and frequency of restaurant meals per
week to account for potential confounders including life-
style (models 2b and 3b) using characteristics measured
cross-sectionally with leptin levels for each respective
model. We also performed linear regression analyses
according to initial 1st trimester BMI categories as
internationally defined (BMI <25 kg/m2 = normal weight;
25 ≤BMI <30 kg/m2 = overweight; or BMI ≥30 kg/m2 =
obese) to assess associations between leptin levels (per one
log increase) and subsequent GWG (kg/week) per clinically
defined BMI status. In addition to linear regression analyses
assessing GWG per week (in tables), we performed subsid-
iary linear regression analyses with weight gain expressed
as GWG between 1st and 2nd trimester (mid pregnancy
GWG) and GWG between 2nd and 3rd trimester (late preg-
nancy GWG) for easier interpretation. We also conducted
sensitivity analyses: 1- excluding underweight women
defined as 1st trimester BMI <18.5 kg/m2 (n = 17); 2-
excluding morbidly obese women defined as 1st trimester
BMI >40 kg/m2 (n = 9); and by adding an additional vari-
able in adjusted models, namely: 3- placental weight (avail-
able in 529 deliveries); 4- Matsuda index (insulin
sensitivity index); or 5- AUCinsulin/glucose (insulin secretion
index). P < 0.05 was considered statistically significant. All
the analyses were performed using version 18 of Statistical
Package for the Social Sciences (SPSS) for Windows.
Results
Characteristics of the 675 pregnant women included in
the present study are presented in Table 1. Participants
were 28.2 ± 4.3 years old and 97.2% were of European
descent, similar to the general population of pregnant
women receiving care at our institution [23].
Adiposity and weight gain
At 1st trimester, participants had a median BMI of
23.9[21.5–27.3] kg/m2 and a mean %BF equal to 31.3 ±
8.0 % (see Table 1). At 2nd trimester, median BMI was
26.6[24.1–29.8] kg/m2 and mean %BF was 35.4 ± 6.4 %.
Women gained a mean of 6.7 ± 3.0 kg between 1st and
2nd trimester (weekly GWG= 0.40 ± 0.18 kg/week), and
a mean of 5.6 ± 2.5 kg between 2nd trimester and late
3rd trimester (weekly GWG = 0.54 ± 0.23 kg/week) for a
global mean GWG of 12.2 ± 4.4 kg between the 1st and
the end of the 3rd trimester. Maternal factors at 1st tri-
mester associated with larger subsequent GWG were
lower adiposity levels (lower BMI and %BF) and being
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assessed at an earlier point of the pregnancy (as represented
by gestational weeks). Other factors measured at 1st or 2nd
trimester were weakly or non-significantly associated with
subsequent GWG (see Additional file 1: Table S1). At
delivery, birth weight was 3.408 ± 0.461 kg and placental
weight was 557.4 ± 133.4 g in average. Most maternal
weight and adiposity variables at 1st and 2nd trimester were
positively correlated with birth weight and placental
weight; the strongest associations were observed between
maternal weight or %BF and either birth outcomes (see
Additional file 2: Table S2).
Leptin levels
Leptin levels increased from 1st (8.0[4.5–13.0] ng/ml) to
2nd trimester (10.3[6.1–16.0] ng/ml 1-h post OGTT; see
Table 1), with a increase between 1st and 2nd trimester
of 2.1[−0.5–5.3] ng/ml. Maternal factors positively asso-
ciated cross–sectionally with leptin levels at 1st and 2nd
trimester were adiposity levels (BMI and %BF) and blood
pressures, while other factors were weakly or non-
significantly associated with leptin levels (see Table 2
and Additional file 3: Table S3). Birth weight and placental
weight were also weakly associated with maternal leptin
levels at 1st and 2nd trimester (see Additional file 2: Table
S2); these associations were substantially reduced and
none of them remained significant after adjustments for
maternal BMI.
Leptin levels and subsequent weight gain
Table 3 presents linear regression analyses testing the
associations between leptin levels and subsequent GWG.
In unadjusted analyses, higher 1st trimester leptin
levels were associated with lower mid pregnancy GWG
(β = −1.68, meaning a decrease of 1.68 kg per increase of
one log-leptin at 1st trimester; standard error (SE) = 0.35;
P < 0.0001). After adjusting for 1st trimester gestational
weeks and BMI (model 2a), the direction of effect was re-
versed, meaning that higher leptin levels were associated
with greater GWG (β = 1.32; SE = 0.49; P = 0.007).
Table 1 Characteristics of 675 pregnant women included in
Gen3G at 1st and 2nd trimesters
Characteristics 1st trimester 2nd trimester
Mean ± SD or
median [IQR] or %
Mean ± SD or
median [IQR] or %
Age (years) 28.2 ± 4.3 —
Ethnic background 97.2 —
(% European descent)
Parity (% primiparous) 52.0 —
Gestational weeks 9.4 ± 2.0 26.4 ± 1.0
Body mass index (kg/m2) 23.9 [21.5–27.3] 26.6 [24.1–29.8]
% body fat 31.3 ± 8.0 35.4 ± 6.4
Systolic blood pressure (mmHg) 110.5 ± 9.8 107.3 ± 8.9
Diastolic blood pressure (mmHg) 68.9 ± 6.9 67.4 ± 6.6
Physical activity (kcal/kg/day) 1.1 [0.5–1.9] 0.9 [0.4–1.5]
Nutrition
Fruits & vegetables (per day) 5.6 ± 2.4 6.1 ± 2.5
Restaurant meals (per week) 1.0 [0.5–2.0] 1.0 [0.5–2.0]
Leptin levels non fasting (ng/ml) 8.0 [4.5–13.0] —
Leptin levels during OGTT (ng/ml)
Fasting — 13.3 [8.3–20.6]
1-h post OGTT — 10.3 [6.1–16.0]
2-h post OGTT — 9.6 [5.3–15.3]
Data are presented as mean ± standard deviation (SD) or median (interquartile
range). Variables not normally distributed were log-transformed. At 1st trimester,
ranges of leptin levels were 0.9 to 59.7 ng/ml. At 2nd trimester, ranges of leptin
were 1.1 to 85.8 ng/ml fasting, 0.9 to 56.2 ng/ml 1-h post OGTT, and 0.8 to
53.2 ng/ml 2-h post OGTT. For ethnic background and % body fat at 1st trimester:
n = 671. For gestational weeks at 2nd trimester and body mass index at 2nd
trimester: n = 674. For parity and systolic and diastolic blood pressures at 2nd
trimester: n = 673. For waist circumference at 1st trimester: n = 662. For physical
activity at 1st trimester: n = 666. For nutrition: 641 ≤ n ≤ 667. For % body fat at 2nd
trimester and physical activity at 2nd trimester: n = 669
Table 2 Cross-sectional correlations between women’s
characteristics and leptin levels measured at 1st and 2nd
trimester
Characteristics at 1st trimester Correlationsa with leptin levels
at 1st trimester
r P value
Age (years) 0.04 0.31
Gestational weeks 0.12 0.002
Body mass index (kg/m2) 0.73 <0.0001
% body fat 0.74 <0.0001
Systolic blood pressure (mmHg) 0.21 <0.0001
Diastolic blood pressure (mmHg) 0.25 <0.0001
Physical activity (kcal/kg/day) −0.11 0.005
Nutrition
Fruits & vegetables (per day) −0.09 0.02
Restaurant meals (per week) 0.10 0.01
Characteristics at 2nd trimester Correlationsa with leptin levels 1-h
post OGTTat 2nd trimester
r P value
Gestational weeks −0.04 0.25
Body mass index (kg/m2) 0.67 <0.0001
% body fat 0.69 <0.0001
Systolic blood pressure (mmHg) 0.23 <0.0001
Diastolic blood pressure (mmHg) 0.31 <0.0001
Physical activity (kcal/kg/day) −0.07 0.08
Nutrition
Fruits & vegetables (per day) −0.09 0.02
Restaurant meals (per week) 0.09 0.02
aThese are all Pearson correlations, except for correlations with physical
activity at 1st and 2nd trimester that are Spearman correlations
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Replacing BMI by %BF at 1st trimester (model 3a)
showed flattening of the association and leptin levels
were no longer associated with mid pregnancy GWG
(β = 0.38; SE = 0.52; P = 0.46). Further adjustments for
blood pressure, physical activity, fruit and vegetable
portions per day and restaurant meals per week did not
modify associations in BMI of %BF adjusted models.
Higher 2nd trimester leptin levels were associated with
greater late pregnancy GWG (β = 1.17; SE = 0.31; P =
0.0002 for 1-h post OGTT leptin levels). Associations
were strengthened by adjustment for 2nd trimester gesta-
tional weeks and BMI with effect sizes almost doubling
(β = 2.35; SE = 0.41; P < 0.0001 again for 1-h post OGTT
leptin levels). Replacing BMI by %BF did not modify results
in size or direction of effect. All associations remained
statistically significant after further adjustment for blood
pressure, physical activity, fruit and vegetable portions per
day and restaurant meals per week, all measured at 2nd tri-
mester (β = 2.15; SE = 0.42; P < 0.0001 for 1-h post OGTT
leptin levels). Excluding underweight women (BMI <18.5
kg/m2) or morbidly obese women (BMI >40 kg/m2), or
adding placental weight as an additional co-variable
did not modify the results in sensitivity analyses. Our
sensitivity analyses including insulin sensitivity or in-
sulin secretion indices did not modify the associations.
Linear regression analyses concerning late pregnancy
GWG and 2nd trimester leptin levels measured fasting
and 2-h post OGTT showed similar associations than
those observed with 2nd trimester 1-h post OGTT leptin
levels (see Additional file 4: Table S4).
Leptin levels and subsequent weight gain stratified by
maternal weight status
In order to further investigate the role of initial adiposity
in the association between leptin levels and subsequent
GWG, we performed our analyses stratified by maternal
weight status defined by BMI measured at 1st trimester
(see Table 4). We found no association between 1st tri-
mester leptin levels and mid pregnancy GWG in any
BMI strata, neither in unadjusted nor in multivariate
models (all P > 0.05).
Higher 2nd trimester leptin levels were associated with
greater late pregnancy GWG in normal weight women
(unadjusted β = 1.66, kg per log-leptin levels at 1h-OGTT;
SE = 0.41; P < 0.0001). Associations between leptin levels
and late GWG appeared stronger among overweight
women with effect sizes almost twice the ones observed
in normal weight women (unadjusted β = 3.60; SE = 0.88;
P < 0.0001 – P = 0.05 for interaction between normal
weight and overweight strata). Strength of associations
Table 3 Associations between 1st or 2nd trimester leptin levels and subsequent mid or late pregnancy GWGa
Models Associations: 1st trimester leptin
levels and mid pregnancy GWG
Associations: 2nd trimester leptin levels 1-h
post OGTT and late pregnancy GWG
β ± SE P value β ± SE P value
Model 1: unadjusted −0.08 ± 0.02 <0.0001 0.11 ± 0.03 0.0001
Model 2a: adjusted for BMI and gestational weeks 0.07 ± 0.03 0.01 0.24 ± 0.04 <0.0001
Model 2b: BMI-fully adjusted1 0.07 ± 0.03 0.02 0.21 ± 0.04 <0.0001
Model 3a: adjusted for %BF and gestational weeks 0.01 ± 0.03 0.64 0.20 ± 0.04 <0.0001
Model 3b: %BF-fully adjusted1 0.01 ± 0.03 0.74 0.18 ± 0.04 <0.0001
aAll β represent the change in weight gain (kg) per week associated to a change of 1 log of leptin levels. GWG: gestational weight gain. BMI: body mass index.
%BF: percent body fat. OGTT: oral glucose tolerance test. All models were adjusted with variables measured cross-sectionally with leptin levels of interest. For
example in model 2a, model testing association between leptin levels measured at 1st trimester and mid pregnancy GWG is adjusted for BMI at 1st trimester and
the number of weeks of gestation at the moment of assessment. 1Adjusted for further potential confounders (always measured cross-sectionally to leptin levels
respectively to trimester): systolic and diastolic blood pressures (1st or 2nd trimester), physical activity (1st or 2nd trimester), fruits and vegetables per day (1st or 2nd
trimester) and restaurant meals per week (1st or 2nd trimester)
Table 4 Associations between 1st or 2nd trimester leptin and subsequent GWGa stratified by 1st trimester BMI
Models BMI < 25 kg/m2(n = 406) 25 ≤ BMI < 30 kg/m2(n = 159) BMI≥ 30 kg/m2(n = 110)
β ± SE P value β ± SE P value β ± SE P value
1st trimester leptin levels and mid
pregnancy GWG
Unadjusted 0.02 ± 0.03 0.46 0.10 ± 0.08 0.23 0.01 ± 0.09 0.92
Adjusted1 0.01 ± 0.03 0.60 0.01 ± 0.08 0.88 −0.01 ± 0.10 0.92
2nd trimester leptin levels 1-h post OGTT
and late pregnancy GWG
Unadjusted 0.17 ± 0.04 <0.0001 0.33 ± 0.08 <0.0001 0.12 ± 0.12 0.33
Adjusted1 0.15 ± 0.04 0.0001 0.26 ± 0.09 0.004 0.13 ± 0.12 0.29
aAll β represent the change in weight gain (kg) per week associated to a change of 1 log of leptin levels. 1 Adjusted for variables measured cross-sectionally to leptin
levels of interest respectively to trimester: the number of weeks of gestation at the moment of assessment, systolic and diastolic blood pressures (1st or 2nd trimester),
physical activity (1st or 2nd trimester), fruits and vegetables per day (1st or 2nd trimester) and restaurant meals per week (1st or 2nd trimester). BMI: body mass index.
GWG: gestational weight gain. OGTT: oral glucose tolerance test
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was slightly reduced by adding potential confounders in
fully adjusted models for normal weight and overweight
women, mainly driven by presence of blood pressure and
consumption of fruits/vegetables in the models. We ob-
served no significant associations between 2nd trimester
leptin levels and late pregnancy GWG in obese women
(unadjusted β = 0.85; SE = 1.29; P = 0.51 for 1-h post
OGTT leptin levels) in either unadjusted or adjusted
analyses. After removing women with BMI >40 kg/m2
from the obese group, we observed that the effect size
was slightly greater (unadjusted β = 1.66; SE = 1.38; P =
0.23 for 1-h post OGTT leptin levels; n = 101 women) but
this remained non-significant. Our sensitivity analyses ex-
cluding underweight women (BMI <18.5 kg/m2) or in-
cluding either placental weight, insulin sensitivity index or
insulin secretion index as co-variables did not modify the
results. Linear regression analyses using 2nd trimester lep-
tin levels measured fasting and 2-h post OGTT showed
similar associations than those observed with 1-h post
OGTT leptin levels (see Additional file 5: Table S5).
Discussion
We demonstrated that higher 2nd trimester leptin levels
were associated with greater subsequent GWG in pregnant
women from a general population cohort, independent of
maternal adiposity and other confounders. This positive as-
sociation is the opposite of the expected physiologic regula-
tion observed in non-pregnant individuals. Interestingly,
this positive association was particularly observable and
stronger in women classified as overweight at the beginning
of pregnancy than in normal weight women.
Only a few studies have reported associations between
baseline maternal leptin levels – measured at the beginning
of the weight gain period – and subsequent GWG [19–21].
Our findings at 1st trimester are in line with previous find-
ings from Walsh et al. and Kim et al., where 1st trimester
leptin levels do not show a significant association with
subsequent GWG after adjustments for %BF and other
confounders [19, 21]. Thus, based on our results and
those of others, lower 1st trimester leptin levels represent
lower adiposity, signaling the need to increase positive
energy balance and leading to greater weight gain early
in pregnancy – similar to non-pregnant leptin’s role into
central nervous system (CNS) signaling.
Our study adds to the current literature by investigating
leptin levels measured at 24–28 weeks and subsequent
GWG in a wide range of maternal BMI status. In contrast
to our results, Kim et al. did not show associations be-
tween leptin levels measured at 24 weeks and any weight
variables, including GWG. Difference in populations or
limited power due to a smaller sample size (n = 75) may
explain different findings from Kim et al. [21]. Walsh et al.
measured leptin at 28 weeks, but assessed association with
overall GWG throughout pregnancy – i.e. spanning a time
period before and after our leptin measurement, and thus,
we cannot compare their results to ours [19]. In line with
our results in normal weight pregnant women, Stein et al.
reported that higher leptin levels measured at 17 weeks of
gestation were associated with a higher measured rate of
weight gain between 20 and 36 gestational weeks in
women with a pregravid BMI from 19.8 to 26.0 kg/m2
[20]. Our results expand current knowledge and suggest
that this positive association is more prominent in over-
weight women. This is highly intriguing, as we know that
clinically, overweight women are more likely to gain exces-
sive GWG compared to normal weight and obese women.
The physiologic role of leptin during pregnancy is still
obscure, but our results suggest that leptin promotes
weight gain in a feed-forward mechanism during the
second half of pregnancy. The placenta produces leptin
in high quantity and contributes to maternal circulating
levels throughout pregnancy, but why the placenta pro-
duces such a high quantity of leptin remains in question.
Our results showing larger effect size in overweight
women argue for the existence of this feed-forward regula-
tion, as overweight women presented higher levels of
leptin throughout pregnancy: if a pregnancy-specific
CNS signal emerges as pregnancy advances, rising
placental-derived leptin, in addition to high leptin from
pre-pregnancy overweight status, might enhanced this
positive feed-forward loop. Our findings of reduced as-
sociations in obese women could be explained by a
state of central leptin resistance when levels reach the
extreme upper range; but they could also reflect obese
women self-regulating their energy balance based on
clinical recommendations. It is also possible that leptin
resistance occurring at the placenta level contributes to
the absence of this feed-forward mechanism in obese
women [29, 30]. However, the reduced effect sizes we
observed in obese women should be interpreted with
caution, given large confidence intervals and our smaller
sample in this stratum.
Animal studies have supported the existence of a
pregnancy-induced leptin resistance status [31–34]. For
example, Ladyman et al. observed that intraperitoneal
injections of leptin did not suppress food intake in preg-
nant mice compared to its observed effect of food intake
reduction in non-pregnant mice [31]. The same report
also demonstrated that the ventromedial hypothalamus
and the paraventricular nucleus of pregnant mice showed
a decrease in leptin sensitivity compared to non-pregnant
mice [31]. Based on animal models, other potential mech-
anisms that could contribute to leptin resistance during
pregnancy include an increase in circulating leptin binding
protein, an impairment in leptin transport through the
blood brain barrier, a decrease in Ob-Rb (isoform b of
leptin’s receptor) mRNA (messenger ribonucleic acid)
levels in the hypothalamus, and/or an impairment in
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the intracellular signalization induced by the binding of
leptin to Ob-Rb [32–34]. In term human placenta tis-
sue sections from obese pregnancies, it has also been
shown that Ob-Rb is down regulated in comparison to
lean pregnancies, raising the possibility of placental leptin
resistance [29, 30]. Our results add to the current know-
ledge in suggesting that a state of leptin resistance also
exists in human pregnancy, though the exact mechanisms
leading to pregnancy-induced leptin resistance and a pos-
sible feed-forward loop in humans remain to be investi-
gated. It did not seem that insulin resistance or insulin
secretion influenced our observations, but other factors
such as specific pregnancy hormones may be implicated
and merit future investigations.
Strengths and limitations
A major strength of our study is the design, as participants
were followed prospectively and represent the general
population of pregnant women receiving care at our
hospital [35]. Strengths of this study also include our
large sample size, exclusion of diabetes at 1st and 2nd
trimester, and use of standardized procedures with high
reliability for all laboratory and clinical measures, including
anthropometry.
The main limitation of our study is the observational
study design; consequently, we cannot conclude about
causality or any mechanistic pathways. Despite being
validated in pregnancy [36], measurement of %BF by
bioimpedance could be influenced differently at 2nd tri-
mester by the presence of larger amount of body water,
the placenta and the fetus. We used validated question-
naires for self-report of physical activity and nutrition,
but direct measurements of energy intake and expenditure
would have provided greater precision. Our population is
mainly of European descent, so our results might not
apply to other ethnicities.
Conclusions
In summary, our results suggest that body weight regula-
tion by leptin during the second half of pregnancy does
not follow the physiologic role as an adipostat with
negative feedback to CNS that is classically attributed to
leptin. We revealed a positive association between higher
2nd trimester leptin levels and greater subsequent GWG
in normal weight women, and this association was stron-
ger in overweight women. Our findings suggest a potential
feed forward mechanism where higher leptin levels could
signal the need to increase food intake and lead to greater
weight gain. Feed forward loops are rare in human physi-
ology, but are well known in the reproductive endocrine
system – such as the menstrual cycle [37]. Mechanistic
studies will be necessary to test this hypothesis and eluci-
date these mechanisms at the CNS and peripheral levels.
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